POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphoma

Fig. 1. Overview the survival outcome of all patients and confirm POD24 as a prognostic marker for outcome. Kaplan-Meier analysis of (A) overall survival and (B) progression-free survival of all patients with mantle cell lymphoma. (C) Spline curve showing the predicted hazard ratio of time to POD from start of frontline treatment as a prognostic marker. (D) Time-dependent receiver operating characteristic (ROC) curve for predicting 3-years survival of POD12 and POD24. POD24: Progression of disease within 24 months; POD12: Progression of disease within 12 months.

Fig. 2. Risk prognostic factors associated with overall survival in patients with MCL. Kaplan-Meier curves of OS for MCL patients according to (A) the age, (B) the LDH, and (C) the MIPI score, (D) the Splenomegaly, (E) the Ki67, (F) the MIPI score and (G) the POD24. MCL: Mantle cell lymphoma; POD24: Progression of disease within 24 months; LDH: Lactate dehydrogenase; MIPI: mantle cell lymphoma international prognostic index, Ki67: cell proliferation marker, POD24: Progression of disease within 24 months.

Fig. 3. A nomogram based on the POD24 combined with clinical factors signature. (A) Construction of a nomogram to forecast 3- and 5-years survival by the model. (B) The calibration chart shows that the predicted survival rate is consistent with the actual survival rate for 3-years and 5-years.

Fig. 4. Estimate the prognostic accuracy of the POD24 combined with clinical factors signature-based nomogram to predict 3- and 5-years survival in mantle cell lymphoma patients. Time-dependent receiver operating characteristic curve analysis for clinical risk factors only, the POD24, and POD24 combined with clinical risk factors for prediction 3- (A) and 5-years (B) survival of patients.